CNX-774 is an experimental compound primarily investigated for its potential in cancer therapy, specifically as a selective androgen receptor degrader (SARD). It is designed to target and degrade androgen receptors in prostate cancer cells, making it a candidate for treating castration-resistant prostate cancer (CRPC), where traditional hormone therapies become ineffective. By promoting the breakdown of androgen receptors, CNX-774 helps suppress tumor growth and may overcome resistance seen with conventional anti-androgens. Its development focuses on improving efficacy and reducing side effects compared to existing treatments. Currently, it remains under preclinical or early clinical evaluation, with research ongoing to determine optimal dosing, safety, and therapeutic impact.